Document Detail

Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension.
MedLine Citation:
PMID:  16100159     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine whether lipid microspheres containing prostaglandin E1 (lipo-PGE1) improve pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension (PAH). METHODS: Forty-nine patients with PAH (8 patients with primary pulmonary hypertension, 21 patients with collagen vascular disease, 20 patients with congenital systemic-to-pulmonary shunts) were randomly classified into a conventional therapy group (n = 22) or a group receiving lipo-PGE1 plus conventional drugs (lipo-PGE1 group; n = 27). Echocardiographic pulmonary parameters, New York Heart Association (NYHA) functional class, and Bruce treadmill test results for exercise capacity were recorded before and after treatment. RESULTS: After 2 weeks of treatment with lipo-PGE1 (10 microg bid for 14 days), there were significant improvements in the values (+/- SD) for systolic pulmonary arterial pressure (SPAP) [76.9 +/- 27.9 mm Hg vs 66.5 +/- 22.8 mm Hg, p < 0.001]; total pulmonary resistance (27.2 +/- 13.3 vs 20.2 +/- 10.7, p < 0.001); left ventricular ejection fraction (58.7 +/- 9.6% vs 64.4 +/- 6.8%, p < 0.001); and cardiac output (3.1 +/- 0.8 L/min vs 3.7 +/- 1.1 L/min, p < 0.01). The NYHA functional class decreased from 3.0 +/- 0.6 to 2.5 +/- 0.6 (p < 0.001), and the exercise capacity increased from 2.8 +/- 1.0 to 4.3 +/- 1.3 metabolic equivalents (MET) [p < 0.001]. Compared with the conventional therapy group, the lipo-PGE(1) group achieved significant reduction of SPAP (10.4 +/- 10.3 mm Hg vs 2.2 +/- 5.6 mm Hg, p = 0.002) and a significant elevation of exercise capacity (1.5 +/- 0.9 MET vs 0.6 +/- 1.1 MET, p = 0.018). CONCLUSION: Lipo-PGE1 can decrease pulmonary artery pressure and increase exercise capacity in patients with PAH.
Jieyan Shen; Ben He; Binyao Wang
Related Documents :
3303379 - Cardiopulmonary exercise testing to assess respiratory impairment in occupational lung ...
11901909 - Functional evaluation before lung resection.
23029189 - Combined effect of ampk/ppar agonists and exercise training in mdx mice functional perf...
11401059 - Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulm...
18851729 - The usefulness of contrast during exercise echocardiography for the assessment of systo...
8088099 - Exercise testing in the evaluation of impairment and disability.
11770789 - Validating motivational readiness for exercise behavior with adolescents.
8338189 - Effect of overlearning on the feeling of knowing is more detectable in within-subject t...
22629249 - Effects of physical activity and inactivity on muscle fatigue.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Chest     Volume:  128     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-15     Completed Date:  2005-09-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  714-9     Citation Subset:  AIM; IM    
Department of Cardiology, Shanghai Second Medical University--Affiliated Renji Hospital, 1630 Dong Fang Rd, Shanghai 200127, Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alprostadil / administration & dosage*,  pharmacology
Drug Delivery Systems
Hemodynamics / drug effects*
Hypertension, Pulmonary / drug therapy*,  physiopathology*
Middle Aged
Prospective Studies
Treatment Outcome
Vasodilator Agents / administration & dosage*,  pharmacology
Reg. No./Substance:
0/Lipids; 0/Vasodilator Agents; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prost...
Next Document:  Massive hemoptysis in cystic fibrosis.